|Thursday - October 1, 2020|
|dalle 14.00||Accesso partecipanti|
|14.15-14.30||Meeting Introduction and Authority Salutations
Towards a Genomic Address in Prostate Cancer Landscape
Johann De Bono
|mHSPC: Which Patients present with Advanced Disease and What We have to Do?
MODERATORI: Enrico Cortesi, Rodolfo Montironi
|15.00-15.15||NGP (Next Generation Pathology): Which Data?
|15.15-15.30||NGI (Next Generation Imaging) Suggestions
Stefano Fanti/ Andrea Farolfi
|15.30-15.45||NGT (Next Generation Treatments). Available Trial’ Data
Alberto Dalla Volta
|15.45-16.00||NGS (Next Generation Sequencing): Where are We going?
|Prostate Cancer “Melting Pot” Debate (AS, MØ CRPC, Sequencing Options, ..): Who treat, When and How ?
MODERATORI: Vittorio Donato, Giuseppe Procopio
|16.45-17.00||NGP (Next Generation Pathology): Identifying Pathological predictor of aggressiveness for MØ CRPC Candidates to “Active Surveillance” or “Active Treatment
|17.00-17.15||NGT (Next Generation Treatments): which 2nd Line CRPC Treatment selection between ARTAs and Docetaxel? Reflecting on the available prospective sequencing Data (CARD)
|17.15-17.30||NGT (Next Generation Treatments): PARP Inhibitors and Immuno-Oncology options in advanced Prostate Cancer, a Niche or more?
|17.30 – 18.00||Open Discussion|
|Friday - October 2, 2020|
Urothelial Cancers: Towards a New Scenario
MODERATORI: Francesco Massari, Claudia Mosillo
|14.00 – 14.15||
NGP (Next Generation Pathology): Looking for innovative Urothelial Cancer Classifications considering eventual Druggable Targets
|14.15 – 14.30||
NGT (Next Generation Treatment): Where are We going in first line?
|14.30 – 14.45||
NGT (Next Generation Treatment): which available and awaited data for the 2nd Lines in Advanced Disease?
|14.45 – 15.00||Open Discussion|
|15.00 – 15.30||
Urothelial Cancers Lecture
What next for urothelial Cancers?
Kidney Cancer Debate: Treatment Choice by Line and Prognostic Factors?
MODERATORI: Annalisa Guida, Roberto Sabbatini
|15.30 – 15.45||
NGP (Next Generation Pathology): what’s about Innovative Histological details also considering eventual Druggable Targets
|15.45 – 16.00||
NGT (Next Generation Treatment): Optimal candidates to different Approaches in the 1st Line Setting
|16.00 - 16.15||
NGT (Next Generation Treatment): Which possible Options in the “new Following Lines” Scenario?
|16.15 – 16.30||Open Discussion & Round Table|
|Advanced Kidney Cancer Lecture|
May We speak of a possibility of a Cure?
|17.00-17.30||Critical Synthesis with Prize for the Best 2020 Communication in GU Oncology and salutation to the 9th WTC-GU 2021 Edition|
|17.30-18.00||Closing Remarks and Take home message|